Harout Khanjian
Optometrist · van Nuys, CANPI 1467878249
Payments from drug & device makers
Across 413 payments — averaging $87.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$22K
- AbbVie$7K
- Sun Pharmaceutical Industries Inc.$1K
- Alcon$996
- Tarsus Pharmaceuticals, Inc.$812
- Oyster Point Pharma, Inc.$677
- plus $3K from 15 others
What the payments were for
- Consulting fees$2,4007%
- Speaking & faculty fees$21,42559%
- Travel & lodging$1,4184%
- Food & beverage$10,80930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 110 | $22,394 |
| AbbVie(2 entities) | 36 | $6,842 |
| Sun Pharmaceutical Industries Inc. | 68 | $1,282 |
| Alcon | 44 | $996 |
| Tarsus Pharmaceuticals, Inc. | 29 | $812 |
| Oyster Point Pharma, Inc. | 29 | $677 |
| Novartis | 29 | $602 |
| Glaukos Corporation | 3 | $452 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $327 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $273 |
| Shire North American Group Inc | 10 | $256 |
| Dompe US, Inc. | 10 | $245 |
| Aerie Pharmaceuticals, Inc. | 7 | $236 |
| Eyevance Pharmaceuticals LLC | 9 | $181 |
| Harrow Eye, LLC | 4 | $129 |
| Akorn Operating Company LLC | 5 | $104 |
| Amgen | 4 | $88 |
| Thea Pharma Inc. | 3 | $64 |
| Coopervision Inc. | 2 | $55 |
| Akorn, Inc. | 1 | $24 |
| Biotissue Holdings Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,052 in reported general payments places this provider in the 95th percentile of 6,778 optometrist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 1,759 | $1,202,303 |
| MieboPerfluorohexyloctane/Pf | 1,021 | $790,525 |
| RestasisCyclosporine | 747 | $489,542 |
| VyzultaLatanoprostene Bunod | 921 | $247,854 |
| EysuvisLoteprednol Etabonate | 461 | $227,349 |
| Cyclosporine | 472 | $151,145 |
| TyrvayaVarenicline Tartrate | 222 | $132,616 |
| LumiganBimatoprost | 411 | $117,230 |
| XdemvyLotilaner | 26 | $47,080 |
| CequaCyclosporine | 78 | $45,467 |
| CombiganBrimonidine Tartrate/Timolol | 191 | $42,410 |
| AzoptBrinzolamide | 84 | $34,681 |
| ZyletTobramycin/Lotepred Etab | 96 | $30,467 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 121 | $24,289 |
| Alphagan PBrimonidine Tartrate | 103 | $23,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $22,394 | $2,240,6823,701 claims |
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $6,842 | $673,0511,452 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $677 | $132,616222 claims |
| AlconAzopt, Simbrinza | $996 | $58,970205 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $812 | $47,08026 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,282 | $45,46778 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCZylet, Prolensa | $327 | $41,224128 claims |
| Thea Pharma Inc.Iyuzeh | $64 | $11,50837 claims |
| Akorn, Inc.Zioptan | $24 | $8,86835 claims |
| Eyevance Pharmaceuticals LLCZerviate | $181 | $8,43339 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,778 optometrist providers in California.
Other optometrist in van Nuys
- Meng LinBerkeley$6.9M
- Steve YoelinNewport Beach$6.1M
- Matthew GellerSpring Valley$3.5M
- David Kasanoffla Mesa$1M
- Colton HeinrichFullerton$987K
- Elsa PaoOakland$910K
- Keith WanSan Diego$887K
- Selena ChanSan Francisco$677K
- Melissa EricksonDavis$522K
- Omid KhodaiLake Forest$499K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.